Specialised Therapeutics welcomes the registration of YORVIPATH by the Therapeutic Goods Administration, “for the treatment of chronic hypoparathyroidism in adults”. YORVIPATH was granted an ...

How Does Yorvipath Work for Hypoparathyroidism? Yorvipath works as a replacement for parathyroid hormone if your body does not make enough parathyroid hormone. This means that Yorvipath helps your ...

Yorvipath (palopegteriparatide) is a prescription drug that’s used to treat underactive parathyroid glands. Yorvipath comes as a liquid solution that you inject under your skin. Yorvipath is ...

Leading Australian Endocrinologist and Head of the School of Clinical Sciences at Monash Health, Professor Peter Ebeling AO, applauded the TGA approval of YORVIPATH in addressing an unmet medical ...

Mikkelsen announced the commercial launch of YORVIPATH in the U.S., with 908 unique patient prescriptions as of February 7, 2025. The product targets the treatment of hypoparathyroidism and is ...

YORVIPATH revenue for the fourth quarter of ... website shortly after conclusion of the event for 30 days. This press release contains forward-looking statements that involve substantial risks ...

Yorvipath saw 908 U.S. prescriptions by Feb. 7, 2025, while Skytrofa sales hit €58.5M. The board approved a $18.25M share repurchase plan. Every week, our Whisper Index uncovers five overlooked ...

Examples of such statements may include, but are not limited to, statements regarding our commercialization and continued development of SKYTROFA and YORVIPATH ... s press release and the risk ...

A prodrug of parathyroid hormone (PTH [1-34]), YORVIPATH is administered subcutaneously once daily, with sustained release of active PTH designed to provide PTH levels in the physiological range ...